22/05/2018
A laboratory that takes care of its employees

The following article shows a clear example of best practices at work and how important it is to have employees happy and satisfied at the workspace i...

Read More

22/05/2018
Galcanezumab-Cluster headache

Prevention of episodic cluster headache: Primary endpoint achieved in Phase 3 study 16/05/2018 Eli Lilly and Company announced that Galcanezumab met w...

Read More

18/05/2018
New Drug Offers Hope to Millions With Severe Migraines

The first medicine designed to prevent migraines was approved by the Food and Drug Administration on Thursday, ushering in what many experts believe w...

Read More

07/05/2018
EPF publishes a guide for patient organisations on the new Data Protection Regulation

The new Regulation on personal data protection (EU/2016/679) was published in May 2016 and will apply from May 2018. It provides more rights to citize...

Read More

07/05/2018
Migraines are associated with a polygenic inheritance

A new study has found that some families are especially sensitive to migraines and that genetics influences the type of migraine suffered by affected...

Read More

30/04/2018
CGRP as the target of new migraine therapies — successful translation from bench to clinic

You can now download the document here:  ----->  CGRP as the target of new migraine therapies — successful translation from bench to clinic...

Read More

27/04/2018
Potential source of gender differences in migraines

Findings from a new study conducted in rats reveal that females may be more susceptible to migraines and less responsive to treatment because of the w...

Read More

18/04/2018
European Patients’ Rights Day, TODAY, April 18

Patients claim their right to participate in Decision about their HEalth Patients have the right to participate in making decisions about their health...

Read More

23/03/2018
New measures to avoid valproate exposure in pregnancy

The Coordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh) has endorsed new measures to avoid exposure of babies to val...

Read More

12/02/2018
PRAC recommends new measures to avoid valproate exposure in pregnancy

The European Medicines Agency’s experts in medicines safety, the Pharmacovigilance Risk Assessment Committee (PRAC) are recommending new measures to...

Read More
A laboratory that takes care of its employees
The following article shows a clear example of bes...
Galcanezumab-Cluster headache
Prevention of episodic cluster headache: Primary e...
New Drug Offers Hope to Millions With Severe Migraines
The first medicine designed to prevent migraines w...
EPF publishes a guide for patient organisations on the new Data Protection Regulation
The new Regulation on personal data protection (EU...
Migraines are associated with a polygenic inheritance
A new study has found that some families are espec...
CGRP as the target of new migraine therapies — successful translation from bench to clinic
You can now download the document here:  -----�...
Potential source of gender differences in migraines
Findings from a new study conducted in rats reveal...
European Patients’ Rights Day, TODAY, April 18
Patients claim their right to participate in Decis...
New measures to avoid valproate exposure in pregnancy
The Coordination Group for Mutual Recognition and...
PRAC recommends new measures to avoid valproate exposure in pregnancy
The European Medicines Agency’s experts in medic...
Home 2017-07-19T12:26:14+00:00

All EHA Members

What is EHA?

The European Headache Alliance is a non-profit, patient umbrella group which was launched in 2006. Since then, the Alliance has grown to represent 25 patient groups from across the continent.

The development of European umbrella organisations is a natural progression with more relevance for European nations.

Read More

About Headache

Headache disorders are among the most common disorders of the nervous system. These include tension-type headache (TTH), migraine and chronic daily headache syndromes as well as the more rare disorders, cluster headache and trigeminal neuralgia.

Read More

datas
EHA Data charts

Statistical data

In 2010, EHA launched its Madrid Manifesto for Migraine/ Headache Disorders at the Spanish Parliament to mark European Migraine Day of Action. This document outlined our 5-year objectives to improve migraine management, education and awareness across Europe.

Projects

EHA is the result of the need of making society know the different types of migraine that exist and that currently are not receiving the importance they deserve. EHA fights for the human rights, that is why is present in activities and events that are relevant for headache issues. Trying to give voice for those ones who need it. EHA works as well in finding a way to mitigate migraine, by joining forces and strengthening partnerships which are aiming the same objective.

Utilizamos cookies propias y de terceros para el correcto funcionamiento del portal y de sus complementos, reproducir conteido multimeda, interactuar con redes sociales y realizar analíticas de navegación. Si continúas navegando aceptas el uso de dicha tecnología, para más información visita nuestra política de cookies. Find out more

Los ajustes de cookies de esta web están configurados para "permitir cookies" y así ofrecerte la mejor experiencia de navegación posible. Si sigues utilizando esta web sin cambiar tus ajustes de cookies o haces clic en "Aceptar" estarás dando tu consentimiento a esto.

Cerrar